Pediatrics - Allergy and Immunology
Practice Guideline: Prevention and management of allergic reactions to food in child care centers and schools
11 May, 2021 | 09:06h | UTC
Commentary on Twitter (thread – click for more)
Many clickbait headlines are misrepresenting new guidelines on managing #foodallergy in schools.
This is a nuanced topic and these guidelines evaluated all available evidence surrounding reactions in the school setting.
Access here: https://t.co/RIhfAmTSVd
My thoughts 🧵⬇️
— Dr. Dave Stukus (@AllergyKidsDoc) May 7, 2021
Study shows low incidence of post-acute COVID-19 symptoms (“Long Covid”) in children after mild disease
22 Apr, 2021 | 08:40h | UTC
Commentaries on Twitter
Early data from @RCHMelbourne show that, at 3-6 month follow-up, all 151 children with mild and asymptomatic #COVID19 had returned to their baseline health status and post-acute COVID-19 symptoms had resolved.
Letter from @Shidan_Tosif & colleagues: https://t.co/XXa0EPIgPY
— The Lancet Child & Adolescent Health (@LancetChildAdol) April 20, 2021
Given such little available data, this study from Australia on post-acute COVID-19 symptoms in children is very important
Findings are extremely reassuring
Post-acute symptoms were rare, and mild (cough 4%, fatigue 2%, cough and fatigue 1%)
Great news!https://t.co/TEJyES3Crx
— Alasdair Munro (@apsmunro) April 21, 2021
Great to see research looking at whether long Covid is a problem in children.
From this Melbourne cohort, enduring cough and fatigue are uncommon.
It hasn’t been clear to me whether borders will reopen before children are vaccinated so this is VIP https://t.co/iLXqwXJmOt
— Jin Russell (@DrJinRussell) April 21, 2021
Truly encouraging data on post-acute #COVID19 in children. Single-center in Australia. n=151.
8% post-acute symptoms – all symptomatic COVID-19.
Mild symptoms: cough 4%, fatigue 2%, both 1%. Duration: cough 3-8w; post-viral fatigue 6-8w. All solved in follow-up time 3-6 months. https://t.co/vKrEFZlw3C— Dr Pablo Guisado Vasco MD, PhD (@PabloGVasco) April 21, 2021
[Press release – not published yet] Pfizer-BioNTech vaccine 100% effective against Covid-19 in adolescents
1 Apr, 2021 | 03:52h | UTCPress release: Pfizer-BioNTech Announce Positive Topline Results Of Pivotal Covid-19 Vaccine Study In Adolescents
Commentaries: The Pfizer-BioNTech Vaccine Is Said to Be Powerfully Protective in Adolescents – The New York Times AND Covid: Children ‘well protected by Pfizer vaccine’ – BBC AND Pfizer Says COVID-19 Vaccine Shows ‘100% Efficacy’ In Adolescents – NPR AND Pfizer says its COVID-19 vaccine protects younger teens – Associated Press AND Pfizer and BioNTech say vaccine prevents Covid-19 in adolescents – STAT
Commentaries on Twitter
Press release for BNT-Pfizer vaccine efficacy in 2,260 adolescents aged 12 to 15: 0 Covid-19 among vaccinated, 18 in placebo group. Adverse reactions similar to those in 16 to 25 year-olds (no extra data: could be quite high, so eyes on that) https://t.co/mCoLmCtpgv
— Hilda Bastian, PhD (@hildabast) March 31, 2021
This is really terrific
In trial of 2260 adolescents 12-15 year of age, Pfizer vaccine highly effective at preventing infections
18 infections in placebo group
0 infections in vaccine group
Robust antibody response
No serious side-effects
Looking forward to @US_FDA review https://t.co/VymGXOVb5E
— Ashish K. Jha, MD, MPH (@ashishkjha) March 31, 2021
Clinician Guide to COVID-19 diagnostics in children
21 Mar, 2021 | 21:48h | UTCClinician guide to COVID-19 diagnostics – ADC Education & Practice
Cutaneous findings in SARS-CoV-2-associated Multisystem Inflammatory Disease in Children (MIS-C)
23 Feb, 2021 | 01:57h | UTC
A food allergy epidemic… or just another case of overdiagnosis?
19 Feb, 2021 | 02:13h | UTCA food allergy epidemic… or just another case of overdiagnosis? – The BMJ Opinion
Original study: Food anaphylaxis in the United Kingdom: analysis of national data, 1998-2018 – The BMJ
Observational study: The combination of Immunoglobulins + Methylprednisolone was associated with a better course of fever compared to Immunoglobulins alone in Multisystem Inflammatory Syndrome in children
3 Feb, 2021 | 01:39h | UTC
Commentaries on Twitter
In this cohort study, treatment w IVIG + methylprednisolone was associated w lower risk of treatment failure (defined as fever persistence 2d after start of therapy or fever recrudescence within 7 days) vs IVIG alone among children w MIS-C https://t.co/LjEBFuf33q
— JAMA (@JAMA_current) February 1, 2021
Yes, retrospective, but I find these data interesting as I expect the combined treatment group to be the sicker of the 2
Association of IVIG Plus Methylprednisolone With Persistent or Recurrent Fever in Children With MIS-C https://t.co/Oio8t05zQ1 via @JAMA_current @JAMANetwork
— Joshua Denson MD (@jdensonMD) February 2, 2021